11:10-12:00, Rm 103

More documents

Recommendations

Info

Molecular medicine and imagingQ-18-01No immune responses by the expression of the yeast Ndi1 protein inrodentsByoung Boo Seo, Mathieu Marella, Akemi Matsuno-Yagi and Takao YagiDepartment of animal resources, College of life & Environmental Science, Daegu University,Jillyang, Gyeongsan, Gyeongbuk 712-714, Korea, and Department of Molecular and ExperimentalMedicine, MEM-256, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla,California 92037, U.S.A.The rotenone-insensitive internal NADH-Q oxidoreductase from yeast, Ndi1, has beenshown to work as a replacement molecule for complex I in the respiratory chain ofmammalian mitochondria. In the so-called transkingdom gene therapy, one majorconcern is the fact the yeast protein is foreign in mammals. Long term expression of Ndi1observed in rodents with no apparent damage to the target tissue was indicative of noaction by the host’s immune system. In the present study, we examined rat skeletalmuscles expressing Ndi1 for possible sign of inflammatory or immune responses. Thetissues were subjected to H&E staining and immunohistochemical analyses usingantibodies specific for markers, CD11b, CD3, CD4, and CD8. The data showed nodetectable signs of immune responses with the tissues expressing Ndi1. In contrast, mildbut distinctive positive reactions were observed in the tissues expressing GFP. This cleardifference most likely comes from the difference in the location of the expressed protein.Ndi1 was localized to mitochondria whereas GFP was in the cytosol. The current resultspush forward the Ndi1-based molecular therapy and also expand the possibility of use offoreign proteins that are directed to subcellular organelle such as mitochondria.Q-18-04Effects of the asian sand dust - particulate matter on liver fibrosis inC57BL/6 miceGun-Hyun Park, Sung-Hun Bae, Myung-jin Kim, You-Jin HwangDivision of Biological Science, Gachon University of Medicine and Science, Incheon 406-799, KoreaThe Asian Sand Dust - Particulate Matter (ASD-PM) is originated China and Mongoliadesert areas during springtime and is generally thought to threaten the East Asian healthby inducing respiratory illness like laryngopharyngitis and asthma. In this study, weexamined association between The Asian Sand Dust (ASD) fibrosis of mice hepatocyte.C57BL/6 mice were exposed to saline suspensions of ASD particle 3 times weeks for 4weeks, 8 weeks, and 12 weeks. Following exposure with ASD, The liver were analyzedimmunochemistry by hematoxylin and eosin (H&E) and Masson’s trichrome (MT)staining.The mice exposed to ASD during 12 weeks showed significant collagenaccumulation in the liver as compared with the mice exposed to ASD during 4 weeks.Long term exposed rat sample most accumulate collagen in extracellular matrix of rathepatocyte. As a result, ASD-PM accumulates collagen in mice liver and relateshepatofibrosis. Our results suggest that if people or animal exposure to ASD, ASDdamage lung and liver and relate fibrosis.Q-18-02Inhibition of tumor growth by systemic administration of anti-EGFRimmunonanoparticles encapsulating IL-12 and salmosin genesJung Seok Kim, Yeon Kyung Lee, Hwa Yeon Jeong, Young Eun Shin, Keun SikKim¹and Yong Serk ParkDepartment of Biomedical Laboratory Science, Yonsei University, Wonju 220-710, Korea, and¹Department of Biomedical Laboratory Science, Konyang University, Daejeon 302-718, KoreaIt has been suggested that providing of target specificity to liposomal gene deliverysystem may be able to enhance their in vivo transfection efficiency. The epidermal growthfactor receptor (EGFR) is a well known small and stable tumor-associated antigen widelyexpressed in various cancer cells. In this study, we developed four different types ofEGFR-targeted gene delivery system (immunoliposomes, immunovirosomes,immunolipoplexes and immunoviroplexes) by coupling of anti-EGFR antibodies(Cetuximab) to liposomal surface. The anti-EGFR immunonanoparticles showed selectivebinding and effective delivery of pDNA to EGFR-positive cells (A549 and SK-OV-3), butnot to EGFR-negative cells (MCF-7 and B16BL6). Their EGFR-mediated transfectionefficiencies were further enhanced by pDNA condensation by protamine sulfate.Especially, anti-EGFR immunoviroplexes exhibited the most efficient transfection toEGFR over-expressing tumor cells. Anti-EGFR immunolipoplexes and immunoviroplexescontaining two different anticancer genes (IL-12 and salmosine) were prepared andintravenously injected to mice carrying SK-OV-3 tumor. In vivo co-transfection of IL-12and salmosine genes mediated by the anti-EGFR immunonanoparticles was able toeffectively inhibit SK-OV-3 tumor growth in mice.Q-18-05Enhancement of the cancer targeting specificity of buforin IIb by fusionwith an anionic peptide via a matrix metalloproteinases-cleavable linkerJu Hye Jang, Mi Jung Jang, Hyun Kim and Ju Hyun ChoDepartment of Biology, Research Institute of Life Science, Gyeongsang National University, Jinju660-701, KoreaBuforin IIb a novel cell-penetrating anticancer peptide derived from histone H2A. In thisstudy, we enhanced the cancer targeting specificity of buforin IIb using a tumorassociatedenzyme-controlled activation strategy. Buforin IIb was fused with an anionicpeptide (modified magainin intervening sequence, MMIS), which neutralizes the positivecharge of buforin IIb and thus renders it inactive, via a matrix metalloproteinases (MMPs)-cleavable linker. The resulting MMIS:buforin IIb fusion peptide was completely inactiveagainst MMPs-nonproducing cells. However, when the fusion peptide was administratedto MMPs-producing cancer cells, it regained the killing activity by releasing free buforin IIbthrough MMPs-mediated cleavage. Moreover, the activity of the fusion peptide towardMMPs-producing cancer cells was significantly decreased when the cells were pretreatedwith a MMP inhibitor. Taken together, these data indicate that the cancer targetingspecificity of MMIS:buforin IIb is enhanced compared to the parent peptide by reactivationat the specialized areas where MMPs are pathologically produced.Q-18-03Target-specific small interfering RNA delivery by anti-EGFRimmunonanoplexes to EGFR-expressing tumor cellsJung Seok Kim, Yeon Kyung Lee, Hwa Yeon Jeong, Young Eun Shin, Keun SikKim¹and Yong Serk ParkDepartment of Biomedical Laboratory Science, Yonsei University, Wonju 220-710, Korea, and¹Department of Biomedical Laboratory Science, Konyang University, Daejeon 302-718, KoreaEfficient siRNA delivery to cancer cells following systemic administration is the mostdifficult hurdle for clinical applications of siRNA in cancer therapy. The epidermal growthfactor receptor (EGFR) has been recognized as a therapeutic target for treatment ofcancers over-expressing EGFR. In this study, we prepared four different types of anti-EGFR antibody-conjugated nanoparticles (immunoliposomes, immunovirosomes,immunolipoplexes and immunoviroplexes) for EGFR-specific siRNA delivery to tumors.Anti-EGFR immunolipoplexes and immuniviroplexes exhibited significantly enhancedsiRNA delivery to EGFR-expressing tumor cells (A549 and SK-OV-3), resulting ineffective silencing of target gene. But they showed little siRNA transfection to EGFRnegativecells (MCF-7 and B16BL6). Moreover, we have undertaken an anti-cancertherapy using the anti-EGFR immunonanoparticles containing JAK3 siRNA and/orvimentin siRNA in a mouse model carrying SK-OV-3 tumors. Combined in vivotransfection of JAK3 and vimentin siRNA mediated by anti-EGFR immunonanoplexeswas able to effectively inhibit SK-OV-3 tumor growth in vivo. All the experimental resultssuggest that the anti-EGFR immunonanoplex formulation can be widely applied toefficient siRNA delivery to EGFR-overexpressing cancers.Q-18-06Apoptosis of hepatocytes by static magnetic field andsuperparamagnetic nanoparticles: implication of an iatrogeniccytotoxicity by MR imagingJi-Eun Bae¹, Ji-Yeon Do¹, Gang-Ho Lee², Jae-Chang Jung³, Yong-Min Chang⁴,Kwon-Seok Chae¹ , *¹Department of Biology Education, ²Department of Chemistry, ³Department of Biology, and⁴Department of Molecular Medicine and Medical & Biological Engineering, Kyungpook NationalUniversity, Daegu 702-701, KoreaBiomedical applications of superparamagnetic iron oxide (SPIO) as a MR contrast agent(CA) are expanding drastically in recent years. A liver-selective MR contrast agent (CA),ferucarbotran has been competitively used in last decade and it’s adverse effectsincluding cytotoxicity have been considered as marginal and tolerable in patients.However, from the view of electromagnetic biology, it is very reasonable to examinecellular toxicity of superparamagnetic nanoparticles under static magnetic field (SMF). Inthis study, we sought to know whether strong SMF like as MRI field could affect on SPIOcellular toxicity in vitro and in vivo. Concomitant treatments of ferucarbotran and SMF (0.4T in vitro, 1.5 T in vivo) showed synergistic reduction of cellular viability, induction ofapoptosis, and cell cycle aberration whereby the SMF-induced aggregates of the SPIOwere the dominant cause of the cellular toxicity. Interestingly, treatments-induced reactiveoxygen species (ROS) were necessary for the apoptosis but not for the cell viabilityreduction. These results demonstrate for the first time that the SMF provokes asynergistic cellular toxicity of the SPIO in vitro and in vivo and ROS-dependent and -independent features of the cytotoxicity.324 Korean Society for Biochemistry and Molecular Biology
Molecular medicine and imaging
Page 2 and 3:
SecretariatKorean Society for Bioch
Page 4 and 5:
345710111359616498160354404Invitati
Page 6 and 7:
General InformationRegistrationRegi
Page 8 and 9:
Science ManagerMin-Seon KimAsan Med
Page 10 and 11:
Tuesday, May 17, 2011Time8:00-9:00G
Page 12 and 13:
Hall InformationSeminar | Grand Bal
Page 14 and 15:
The poster board surface area is 95
Page 16 and 17:
Nobel Laureate LectureMay 17 (Tue),
Page 18 and 19:
KMA Plenary LectureMay 16 (Mon), 15
Page 20 and 21:
Moosa Plenary LectureMay 17 (Tue),
Page 22 and 23:
Donghun Award LectureSang-Hun LeeDe
Page 24 and 25:
Chungsan Award LectureSue Goo RheeD
Page 26 and 27:
Macrogen Woman Scientist Award Lect
Page 28 and 29:
Achievement Award of Paper - BMB re
Page 30 and 31:
Most Citation Paper Award - BMB rep
Page 32 and 33:
Most Number of Paper Award - BMB re
Page 34 and 35:
Merck Young Scientist Award Lecture
Page 36 and 37:
SymposiaS1Stem Cells and Cancer Ste
Page 38 and 39:
S3Aging and Mitochondria May 16 (Mo
Page 40 and 41:
S5Cell Cycle and Genetic Stability
Page 42 and 43:
S7Reactive Oxygen Species and Cell
Page 44 and 45:
S9Stem Cell and Differentiation-KNI
Page 46 and 47:
S11G-protein Coupled Receptors and
Page 48 and 49:
S13Development and Model Organisms
Page 50 and 51:
S15Innate Immunity and Host-Microbe
Page 52 and 53:
S17Neurodevelopment and Regeneratio
Page 54 and 55:
S19Cardiovascular Disease May 18 (W
Page 56 and 57:
Biomedical Lecture SeriesBLS1Autoph
Page 58 and 59:
BLS3Angiogenesis and Vascular Disea
Page 60 and 61:
BLS5Inflammation and Immunity May 1
Page 62 and 63:
Bio-Medical Science Co., LtdMay 17
Page 65 and 66:
2011KSBMBAnnual MeetingStepping int
Page 67:
KMA Plenary LectureNuclear receptor
Page 70 and 71:
Donghun AwardStem cell biology for
Page 72 and 73:
Stem Cells and Cancer Stem Cells, C
Page 74 and 75:
The Early Stage of Plant Developmen
Page 76 and 77:
Reactive Oxygen Species and Cell Si
Page 78 and 79:
Stem Cell and Differentiation-KNIH
Page 80 and 81:
TGF-βSignaling and Its Therapeutic
Page 82 and 83:
Post-Transcriptional Regulation and
Page 84 and 85:
Neurodevelopment and RegenerationS1
Page 86 and 87:
Cardiovascular Diseaseoxidant, redu
Page 89 and 90:
Page 91 and 92:
Neurodegenerative Disease, Angiogen
Page 93:
Inflammation and Immunity
Page 96 and 97:
GE Healthcare Ltd.High content anal
Page 99 and 100:
Page 101 and 102:
Poster Session List
Page 103 and 104:
Poster Session List
Page 105 and 106:
Poster Session List
Page 107 and 108:
Poster Session List
Page 109 and 110:
Poster Session List
Page 111 and 112:
Poster Session List
Page 113 and 114:
Poster Session List
Page 115 and 116:
Poster Session List
Page 117 and 118:
Poster Session List
Page 119 and 120:
Poster Session List
Page 121 and 122:
Poster Session List
Page 123 and 124:
Poster Session List
Page 125 and 126:
Poster Session List
Page 127 and 128:
Poster Session List
Page 129 and 130:
Poster Session List
Page 131 and 132:
Poster Session List
Page 133 and 134:
Poster Session List
Page 135 and 136:
Poster Session List
Page 137 and 138:
Poster Session List
Page 139 and 140:
Poster Session List
Page 141 and 142:
Poster Session List
Page 143 and 144:
Poster Session List
Page 145 and 146:
Poster Session List
Page 147 and 148:
Poster Session List
Page 149 and 150:
Poster Session List
Page 151 and 152:
Poster Session List
Page 153 and 154:
Poster Session List
Page 155 and 156:
Poster Session List
Page 157 and 158:
Poster Session List
Page 159 and 160:
Poster Session List
Page 161 and 162:
Page 163 and 164:
Bioinformatics and systems biology
Page 165 and 166:
Page 167:
Page 170 and 171:
Cancer biologyB-17-01TrkC plays an
Page 172 and 173:
Cancer biologyB-17-13Syntenin posit
Page 174 and 175:
Cancer biologyB-17-25Role of CBR1 i
Page 176 and 177:
Cancer biologyB-17-38Secretory leuk
Page 178 and 179:
Cancer biologyB-17-50Thymoquinone (
Page 180 and 181:
Cancer biologyB-17-62Omega-3 polyun
Page 182 and 183:
Cancer biologyB-17-74Identification
Page 184 and 185:
Cancer biologyB-17-86Elevated fibro
Page 186 and 187:
Cancer biologyB-17-98Tissue inhibit
Page 188 and 189:
Cancer biologyB-17-111Sox10 control
Page 190 and 191:
Cancer biologyB-17-123Rsf-1 (HBXAP)
Page 192 and 193:
Cancer biologyB-17-135Syndecan-2 re
Page 194 and 195:
Cancer biologyB-17-147Involvement o
Page 196 and 197:
Cancer biologyB-17-159Overexpressio
Page 198 and 199:
Cancer biologyB-17-171IEX-1 is a cr
Page 200 and 201:
Cancer biologyB-17-183Clinical vali
Page 202 and 203:
Cell: differentiation, division and
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 219 and 220:
Page 221 and 222:
Chemical biology and drug discovery
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229:
Page 232 and 233:
Development and regenerationE-17-01
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Lipids and carbohydratesF-17-01Chan
Page 240 and 241:
MicrobiologyG-17-01Fatty acids incr
Page 242 and 243:
MicrobiologyG-17-13MARCH5, a mitoch
Page 244 and 245:
MicrobiologyG-17-25Discovery of che
Page 246 and 247:
NeuroscienceH-17-01N-Adamantyl-4-me
Page 248 and 249:
NeuroscienceH-17-12Inhibition of do
Page 250 and 251:
NeuroscienceH-17-24Neuroprotective
Page 252 and 253:
NeuroscienceH-17-37A novel BDNF-mod
Page 254 and 255:
NeuroscienceH-17-49Differential alt
Page 256 and 257:
NeuroscienceH-17-61Effect of volunt
Page 259 and 260:
Page 261:
Plant biology
Page 264 and 265:
Protein: structure and functionJ-17
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Biotechnology and bioengineeringK-1
Page 274 and 275:
Biotechnology and bioengineeringK-1
Page 277 and 278: 2011KSBMBAnnual MeetingStepping int
Page 279 and 280: Cell: signal transduction
Page 295: Cell: structure and physiology
Page 298 and 299: Genetics and genomics, epigeneticsN
Page 306 and 307: ImmunologyO-18-01Cilostazol protect
Page 308 and 309: ImmunologyO-18-14IL-18 is an import
Page 310 and 311: ImmunologyO-18-26Functions of novel
Page 312 and 313: ImmunologyO-18-39KIAA1542 gene prod
Page 317 and 318: Metabolism and metabolic diseases
Page 323: Metabolism and metabolic diseases
Page 331 and 332: Protein: modification and regulatio
Page 335: Proteomics
Page 338 and 339: RNA biologyT-18-01Genome-wide funct
Page 340 and 341: RNA biologyT-18-14Rapid molecular d
Page 342 and 343: OthersU-18-01Use of non-melanocytic
Page 344 and 345: OthersU-18-13Sulfuretin inhibits UV
Page 346 and 347: OthersU-18-25Suppressed expression
Page 348 and 349: OthersU-18-37Mismatch-repair relate
Page 350 and 351: OthersU-18-49AIP2, one of AROS inte
Page 352 and 353: Launching new technologies from the
Page 354 and 355: KSBMB’s NEXT MEETINGSSorak Confer
Page 356 and 357: 354Exhibition Booth Layout
Page 358 and 359: 기기전시 상호명별 부스번
Page 360 and 361: (주)기산바이오텍 부스번
Page 362 and 363: (주)대한과학 부스번호 : 16
Page 364 and 365: (주)메카시스 부스번호 : 61
Page 366 and 367: l(주)비바젠 부스번호 : 151,
Page 368 and 369: (주)아토코리아 부스번호 :
Page 370 and 371: (주)월드사이언스 부스번
Page 372 and 373: 천양테크 부스번호 : 38lCHUN
Page 374 and 375: 한국바이오래드 주식회사
Page 376 and 377:
Product Indexactivity monitoring동
Page 378 and 379:
iochemicals고마바이오텍㈜ 10
Page 380 and 381:
싸토리우스 코리아 바이오
Page 382 and 383:
cuvettes, elecroporation㈜고려
Page 384 and 385:
싸토리우스 코리아 바이오
Page 386 and 387:
enzyme immunoassay kits고마바이
Page 388 and 389:
㈜대명사이언스 159㈜디케
Page 390 and 391:
implantable instrumentation서린
Page 392 and 393:
micromanipulators㈜라이카 코
Page 394 and 395:
㈜휴컴시스템 137oxygen uptake
Page 396 and 397:
㈜대명사이언스 159㈜부경
Page 398 and 399:
㈜인실리코젠 133㈜케이오
Page 400 and 401:
한독바이오테크㈜ 64tissue c
Page 402 and 403:
Bio Job Fair 2011May 17 ~ 18, 2011H
Page 405 and 406:
Page 407 and 408:
U-18-06Cho, Young Jae ……B-17-18
Page 409 and 410:
Jang, Sei-Heon ………G-17-03Jang
Page 411 and 412:
P-18-31, S-18-08Kim, Jeewoong …
Page 413 and 414:
LLee, Areum …………P-18-29Lee,
Page 415 and 416:
Moon, Yun-Won ……C-17-81Morgan,
Page 417 and 418:
Shin, Jae-Sun ………J-17-31Shin,
show all

11:10-12:00, Rm 103

Create successful ePaper yourself

Delete template?

Save as template?